Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
89.51
+0.69 (+0.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
October 31, 2024
Via
ACCESSWIRE
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
October 22, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
October 19, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
October 09, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
October 09, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
October 07, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
October 02, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
September 23, 2024
The Federal Reserve's recent 50bps rate cut could significantly boost biotech companies by lowering borrowing costs and improving access to capital.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Economy
Interest Rates
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
September 12, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Biotech Breakout: Stocks for Your Watchlist
September 12, 2024
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150.
Via
MarketBeat
Topics
ETFs
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
September 10, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
September 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
August 21, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
August 14, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Second Quarter 2024 Financial Results
August 08, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
July 25, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
July 25, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
July 24, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
July 22, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
July 17, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
July 16, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
MarketBeat Week in Review – 6/17 - 6/21
June 22, 2024
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Gilead Sciences Stock Surges on HIV Treatment Trial Success
June 21, 2024
Gilead Sciences (NASDAQ: GILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial.
Via
MarketBeat
Exposures
Product Safety
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
June 20, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
June 14, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
June 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
June 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.